ANNUAL REPORT 2012 - TiGenix

of the patents and patent applications or
by co-ownership agreements with license
provisions. Where patents are co-owned,
certain types of exploitation of such patents
may be subject to the co-owner’s approval.
Co-ownership Agreements
A number of TiGenix´ patent families are
the result of collaborations with academic
parties, and are jointly owned. Coownership
agreements are in place for all
such patent families with the exception of
WO/2010/092100.
The Universidad Autónoma de Madrid (UAM)
and TiGenix have jointly developed the
following patents :
- “Biomaterial for suturing” (PCT Publication
Number WO2006035083),
- “Identification and isolation of multipotent
cells from non-osteochondral mesenchymal
tissue.” (PCT Publication Number
WO2006037649), and
- “Use of adipose tissue-derived stromal stem
cells in treating fistula.” (PCT Publication
Number WO2006136244).
As agreed in the license executed on
November 3, 2004 and amended on
April 24, 2008, UAM exclusively licensed
rights (including the right to sub-license)
to (the parent applications) P200402355
and P200402083 (and their subsequent
international equivalents as listed above) of
the above patent families to TiGenix.
The Consejo Superior de Investigaciones
Científicas (CSIC) and TiGenix have jointly
developed the patent “Cell populations
having immunoregulatory activity, method
for isolation and uses” (PCT Publication
number WO2007039150). A co-ownership
agreement exclusively licensing all rights was
executed on June 1, 2009.
The University of Seville, CSIC and TiGenix
have jointly developed the patent “Uses of
mesenchymal stem cells” (PCT Publication
Number WO2010015929). A co-ownership
agreement exclusively licensing all rights was
executed on January 17, 2011.
The Centro de Investigaciones Energéticas,
Medioambientales y Tecnológicas (CIEMAT)
and TiGenix have jointly developed the
patent “Use of adipose tissue derived
mesenchymal stem cells for the treatment of
graft versus host disease” (PCT Publication
Number WO2007065927). A co-ownership
agreement was executed on December 2,
2005 recognizing that the patent was jointly
owned and outlining procedures for the joint
prosecution of such.
Patent Portfolio
TiGenix’s commercial success will depend, in
part, on its ability to obtain patent protection
in key markets for certain aspects of its cell
therapy products, processes and related
technologies. TiGenix therefore seeks to
obtain patent protection for these products,
processes and technologies and will
continue to file patent applications in respect
of multiple aspects of its technologies and
products.
TiGenix’s current patent position is as follows :
eASC key base patents :
- “Identification and isolation of multipotent
cells from non-osteochondral mesenchymal
tissue” (PCT Publication WO2006037649) :
73